The Korea Times
Kolon TissueGene announced that it presented long-term follow-up data for TG-C at the World Congress of the Osteoarthritis Research Society International (OARSI), held April 23 to 26 in West Palm Beach, Florida. OARSI is an international organization focused on osteoarthritis research, and its annual congress brings together clinical and scientific experts to share emerging data. At the congress, the company presented long-term follow-up data of up to 17 years for TG-C, along with a subgroup analysis from a Phase 2 study evaluating outcomes by body mass index (BMI). As of July 31, 2025, a total of 219 participants — including five from Phase 1, 33 from Phase 2 and 181 from Phase 3 — had been followed for up to about 17 years in a long-term study. Based on the available data, no new safety signals have been identified so far, and no tumor cases have been deemed related to TG-C. A subgroup of elderly patients monitored for more than a decade also showed no new safety findings during the observation period. A subgroup analysis from a Phase 2 study showed reductions in pain scores in bot
Go to News Site